Sign Up to like & get
recommendations!
0
Published in 2025 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1553
Abstract: Zilurgisertib is an oral, activin receptor‐like kinase 2 (ALK2) inhibitor being developed for the treatment of patients with fibrodysplasia ossificans progressiva. In vitro metabolism studies suggest zilurgisertib is primarily eliminated via cytochrome P450 (CYP) 3A4/5‐mediated…
read more here.
Keywords:
healthy participants;
concomitant administration;
drug;
zilurgisertib ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "MicrobiologyOpen"
DOI: 10.1002/mbo3.1431
Abstract: Rickettsia, a genus of obligate intracellular bacteria, includes species that cause significant human diseases. This study challenges previous claims that the Leucine‐973 residue in the RNA polymerase beta subunit is the primary determinant of rifampin…
read more here.
Keywords:
rickettsia;
rifampin resistance;
genus;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "European journal of clinical pharmacology"
DOI: 10.1007/s00228-020-03057-x
Abstract: PURPOSE To provide practical guidance by providing weekly descriptions of warfarin requirements for the onset and offset of the rifampin-warfarin interaction. METHODS A retrospective chart review within an outpatient Anticoagulation Clinic (AC). Patients were eligible…
read more here.
Keywords:
week;
warfarin;
interaction;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04292-4
Abstract: Fedratinib is an oral and selective Janus kinase 2 inhibitor that is indicated for treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Fedratinib is metabolized by cytochrome P450s (CYPs), primarily CYP3A4. The…
read more here.
Keywords:
moderate cyp3a4;
healthy adult;
strong moderate;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2019.10.021
Abstract: BACKGROUND Rifampin induces the metabolism of many medications. To overcome the reduction in serum concentrations of lopinavir/ritonavir (LPV/r) when used with rifampin, 800/200 mg or 400/400 mg doses are used. OBJECTIVES To evaluate the super-boosted…
read more here.
Keywords:
super boosted;
hiv;
mcg;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Respiratory medicine"
DOI: 10.1016/j.rmed.2017.08.002
Abstract: BACKGROUND Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease. Current guidelines recommend that RMR-TB be treated as multidrug-resistant TB (MDR-TB) but the evidence is scarce. METHODS We conducted a retrospective cohort study on pulmonary…
read more here.
Keywords:
retrospective cohort;
treatment;
rmr;
standard regimen ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "International Journal of Phytoremediation"
DOI: 10.1080/15226514.2022.2093834
Abstract: Abstract In the present study, sisal–Fe/Zn LDH bio-nanocomposite for efficiently removing rifampin was synthesized using a simple co-precipitation method. SEM, XRD, and FTIR analyses were applied to characterize the prepared composite. In the following, different…
read more here.
Keywords:
adsorption;
sisal ldh;
sisal layered;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/ciy346
Abstract: Background Bacterial susceptibility is categorized as susceptible, intermediate-susceptible dose-dependent (ISDD), and resistant. The strategy is to use higher doses of first-line agents in the ISDD category, thereby preserving the use of these drugs. This system…
read more here.
Keywords:
rifampin isoniazid;
susceptibility;
treatment;
dose dependent ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac473
Abstract: Abstract Background Rifampin is recommended as adjunctive therapy for patients with a Staphylococcus aureus prosthetic joint infection (PJI) managed with debridement, antibiotics, and implant retention (DAIR), with no solid consensus on the optimal duration of…
read more here.
Keywords:
optimal duration;
rifampin treatment;
staphylococcus aureus;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac582
Abstract: Abstract Whether rifampin benefits retained staphylococcal prosthetic joint infection is unsettled. In a meta-analysis of 8 studies, we found greater clinical cure with fluoroquinolone-rifampin vs all other regimens (odds ratio [OR], 2.68; 95% CI, 1.43–5.02),…
read more here.
Keywords:
staphylococcal prosthetic;
prosthetic joint;
joint infection;
rifampin ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac583
Abstract: Abstract Background Based primarily on in vitro and animal models, with little data directly addressing patient outcomes, current guidelines recommend treating staphylococcal prosthetic valve endocarditis (PVE) with antibiotic combinations including gentamicin and rifampin. Here, we…
read more here.
Keywords:
staphylococcal prosthetic;
prosthetic valve;
pve;
rifampin ... See more keywords